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2Abstract23
Aspergillus fumigatus causes life-threatening lung infections in immunocompromised24
patients. Mouse models are extensively used in research to assess the in vivo efficacy25
of antifungals. In recent years, there has been an increasing interest in the use of non-26
invasive imaging techniques to evaluate experimental infections. However, single27
imaging modalities have limitations concerning the type of information they can28
provide. In this study, magnetic resonance imaging and bioluminescence imaging were29
combined to obtain longitudinal information on the extent of developing lesions and30
fungal load in a leucopenic mouse model of IPA. This multimodal imaging approach31
was used to assess changes occurring within lungs of infected mice receiving32
voriconazole treatment starting at different time points after infection. Results showed33
that IPA development depends on the inoculum size used to infect animals and that34
disease can be successfully prevented or treated by initiating intervention during early35
stages of infection. Furthermore, we demonstrated that reduction of the fungal load is36
not necessarily associated with the disappearance of lesions on anatomical lung37
images, especially when antifungal treatment coincides with immune recovery. In38
conclusion, multimodal imaging allows to investigate different aspects of disease39
progression or recovery by providing complementary information on dynamic40
processes, which are highly useful for assessing the efficacy of (novel) therapeutic41
compounds in a time- and labor-efficient manner.42
3Introduction43
Aspergillus fumigatus is an opportunistic pathogen which is ubiquitous in the44
environment (1). Inhalation of fungal spores can result in invasive pulmonary45
aspergillosis (IPA), especially in patients with prolonged neutropenia or underlying46
hematopoietic malignancies (2-5). Voriconazole and isavuconazole are recommended47
first line treatment options for invasive aspergillosis (6, 7). In addition to antifungal48
treatment, reversal of the underlying immunosuppression is also a key element in the49
successful management of IPA (7).50
Preclinical research plays an important role in investigating the pathogenesis of IPA51
and in testing antifungal treatment strategies. In a previous study, we showed that52
anatomical imaging techniques such as magnetic resonance imaging (MRI) and53
computed tomography (CT) are highly suitable to monitor dynamic disease-related54
changes in a leucopenic mouse model of IPA (8). The non-invasive character of these55
techniques did not only allow for the longitudinal visualization of developing lung56
lesions, but also for the quantification of imaging-derived biomarkers such as the lung57
tissue volume. However, besides obtaining insight into structural changes occurring in58
the lung upon infection, it is also crucial to obtain information on fungal growth in order59
to fully comprehend all aspects of developing disease and treatment response. As an60
alternative for standard invasive techniques such as colony-forming unit (CFU)61
counting to assess infection, there has been great interest in using non-invasive62
imaging techniques to quantify the fungal load.63
Bioluminescence imaging (BLI) is an optical technique based on the detection of64
photons, which are generated by an enzymatic reaction upon luciferin substrate65
administration (9). To apply this imaging modality in the infectious diseases field,66
pathogens have to be genetically modified to express the luciferase enzyme. As only67
4viable cells can produce bioluminescent signals, the detected signal can be used to68
determine dynamic changes in the microbial load of an organ. Therefore, the obtained69
read-outs are comparable to results obtained by conventional CFU counting (10). BLI70
has already been used extensively to study bacterial and viral infections in both71
superficially located organs such as the skin and deeply located organs such as the72
lungs (11-19). Unfortunately, transforming fungi to express luciferase turned out to be73
more challenging. Initial studies focused on the transformation of Saccharomyces74
cerevisiae and Candida albicans (20, 21). In vivo, only partial success was obtained75
with the bioluminescent C. albicans strain using Renilla or surface-anchored Gaussia76
luciferase (22-25). It proved to be feasible to monitor superficial infections, but77
limitations in the availability of the substrate coelenterazine and absorption of the78
emitted light (480 nm) by hemoglobin hampered the detection of deep-seated79
infections. These difficulties were overcome by using a codon-optimized firefly80
luciferase, which enabled to study disseminated candidiasis and revealed an81
unexpected persistence of C. albicans in the gall bladder under antifungal therapy (26).82
The firefly luciferase has also been successfully used to monitor invasive aspergillosis83
caused by A. fumigatus (10). In a first approach of using the bioluminescent strain, it84
was possible to visualize the early stages of disease in a cortisone-induced mouse85
model of IPA. However, imaging of late stage disease was hampered by restrictions in86
oxygen and substrate availability at the lesion site due to the strong inflammatory87
response and associated necrosis. Further studies revealed that the choice of immune88
suppressive regimen has an important impact on the evolution of bioluminescence89
during progression of disease (27). In contrast to the cortisone model, disease90
progression in cyclophosphamide-induced mice was associated with a strong increase91
in BLI signal over time due to rapid fungal growth and lung tissue invasion.92
5Furthermore, it was shown that animals treated with lipid amphotericin or voriconazole93
show a transient increase in BLI signal, followed by a clear decrease in case of94
treatment success (28). These results highlight the added value of using BLI for95
obtaining information on changes in fungal burden occurring within the lungs of96
leucopenic mice suffering from IPA.97
In most studies, single imaging techniques are used to assess disease progression98
and treatment response, which strongly limits the amount and type of acquired99
information (8, 10, 28). In this study, both an optical and anatomical imaging technique100
were combined to non-invasively obtain complementary information on IPA101
development in a leucopenic mouse model. Furthermore, the influence of voriconazole102
treatment on both the fungal load and lesion size was longitudinally investigated. The103
aim of this study was to improve our knowledge on the relationship between detected104
lesion and fungal growth in a completely non-invasive manner.105
6Materials and Methods106
Fungal strain107
The bioluminescent Aspergillus fumigatus strain 2/7/1 was used (28). The strain was108
cultured for 3 days at 42°C on diluted Sabouraud agar, containing 10% of the dextrose109
and peptone concentrations used in regular Sabouraud agar. Conidia were harvested110
by flooding the agar with saline-0.1% Tween 80 (Sigma-Aldrich, Diegem, Belgium) and111
gently scraping the surface. The collected suspension was shaken vigorously for 5112
minutes and spores were counted with a Neubauer haemocytometer. The suspension113
was diluted to a final concentration of 2.5 x 107 spores/ml or 1.0 x 107 spores/ml.114
Mouse model115
All animal experiments were carried out in compliance with national and European116
regulations and were approved by the animal ethics committee of KU Leuven. Ten-117
week old male BALB/c mice (Janvier, Le Genest, France) were rendered leucopenic118
by intraperitoneal (IP) injections of 150 mg/kg cyclophosphamide (Sigma-Aldrich,119
Diegem, Belgium) on day 4 and 1 prior to infection. To confirm leucopenia, blood was120
collected from a subset of animals by cardiac puncture and 3.8% trisodium citrate121
dihydrate was added to the sample to prevent coagulation. White blood cells were122
counted on day 0 (n = 3) and day 4 (n = 3) using the Advia 2120i hematology system123
(Siemens Healthcare GmbH, Erlangen, Germany).124
On day 0, the animals were anesthetized with 1.5-2% isoflurane (Abbott Laboratories,125
Queenborough, UK) in 100% oxygen and intranasally instilled with 20 µl of a126
suspension containing either 5 x 105 (high inoculum) or 2 x 105 (low inoculum) A.127
fumigatus spores, as previously described (8). Directly after instillation, the mice were128
positioned upright until normal breathing was resumed. In this manuscript, all times are129
stated relative to the day of inoculation, which will be referred to as day 0.130
7All animals in the treatment groups received daily IP injections of 20 mg/kg131
voriconazole (Vfend®, Pfizer, New York, USA) dissolved in saline. For the high132
inoculum group, treatment was initiated either on the day of infection (day 0; n = 5) or133
on day 1 (n = 5), day 2 (n = 5) or day 3 (n = 5) post infection (PI). Based on the data134
obtained for this high inoculum group, treatment was initiated directly on the day of135
infection (day 0; n = 5) or on day 2 PI (n = 5) for the low inoculum group. To prevent136
rapid metabolization of voriconazole, the drinking water was replaced by 100% grape137
fruit juice (Carrefour brand, Boulogne Billancourt, France) as described before (29).138
The disease course was monitored by acquiring MRI scans before infection (baseline)139
and on day 1, 2, 3, 4, 5 and 14 PI. In addition, in vivo BLI scans were acquired on day140
3, 5 and 9 PI. Non-treated animals (n = 10 for the high inoculum group; n = 5 for the141
low inoculum group) did not receive voriconazole nor grape fruit juice. For these mice,142
daily MRI and in vivo BLI scans were acquired until day 4 PI for the high inoculum143
group and until day 7 PI for the low inoculum group.144
During image acquisition, the mice were anesthetized with 1.5-2% isoflurane in 100%145
O2 administered via a nasal cone. Body weight, posture and body temperature were146
monitored daily. The animals were sacrificed when humane endpoints were reached,147
including a strong loss in body weight (> 25%), lethargy and labored breathing. For all148
treatment groups, the remaining animals that did not reach the humane endpoints were149
euthanized after the last imaging time point. After sacrificing, ex vivo BLI scans of the150
isolated lungs were acquired.151
Bioluminescence Imaging152
Images were acquired using an IVIS Spectrum system (Perkin Elmer). For in vivo153
imaging, anesthetized animals were placed in the flow chamber and D-luciferin was154
injected subcutaneously (126 mg/kg). Next, images were acquired until the peak signal155
8intensity was reached. For ex vivo imaging, the complete lungs were inflated with 500156
µl D-luciferin (7.5 mg) by inserting a catheter (22-gauge) into the trachea, after which157
the tissue was isolated and immediately placed in the flow chamber to perform a scan.158
The BLI images were processed using the Living Image software (version 4.5.4, Perkin159
Elmer, Hopkinton, USA). A circular region of interest (ROI) covering the complete lung160
area was used to measure the total photon flux.161
Magnetic Resonance Imaging162
Images were acquired on a 9.4 Tesla Biospec small animal MRI scanner (20 cm163
horizontal bore size; Bruker BioSpin, Ettlingen, Germany) using a gradient insert164
(maximal field strength of 1200 mT/m) and a 3.5 cm quadrature resonator. Body165
temperature and breathing rate were continuously monitored and kept at physiological166
values during the scans by using a physiological monitoring system (SAII, Stony Brook,167
NY, USA). A 3D prospectively respiratory gated ultrashort echo time (UTE) pulse168
sequence was used with following parameters: 0.03 ms echo time (TE), 15 ms169
repetition time (TR), 5° flip angle (FA), 3.5 cm isotropic field of view (FOV), 128 x 128170
x 128 matrix, 273 µm isotropic resolution and a total acquisition time of 18 minutes (8).171
The acquired MR images were analyzed using an in-house written Mevislab module172
(version 2.6.1; Mevislab Medical Solutions and Fraunhofer MEVIS, Bremen,173
Germany). The lung tissue volume was quantified based on a volume of interest (VOI)174
covering the complete lung by manually delineating a ROI on each image slice,175
excluding the heart and main pulmonary vessels. Based on the receiver gain value of176
individual scan, a variable threshold was used to select all voxels with a signal intensity177
above this threshold. Furthermore, a cumulative image score was determined to semi-178
quantitatively describe lesion development and progression by applying a previously179
described scoring system (8).180
9Fungal load quantification181
After the last imaging time point, all animals were euthanized by an overdose of182
pentobarbital (Nembutal, CEVA Santé Animale, Diegem, Belgium). After performing183
ex vivo BLI, the right lung lobes were removed for fungal load quantification by colony-184
forming unit (CFU) counting. The lungs were weighed and homogenized in 600 µl185
phosphate-buffered saline (PBS). Fivefold dilution series were prepared and plated on186
Sabouraud agar, followed by three days incubation at 30°C and manual counting of187
CFUs (30).188
Histological analysis189
The left lung lobe was isolated, post-fixed (24 hours in 10%-formalin) and embedded190
in paraffin. The entire lung was sectioned (5 µm) and stained with periodic acid-Schiff191
(PAS), staining fungi in red (31).192
Statistics193
The data were analyzed using Prism (version 5.04; GraphPad software, San Diego,194
CA). Repeated measures ANOVA with a Tukey’s post-test was used to investigate195
changes in total photon flux (BLI), lung tissue volume and cumulative image score196
(MRI) over time in the non-treated high inoculum group. Linear regression analysis was197
performed to assess the correlation between BLI and MRI derived biomarkers.198
Student’s t-test was used to evaluate differences in total photon flux (ex vivo BLI) and199
CFU counts between the treated and non-treated groups. Differences were considered200
statistically significant if p-value < 0.05. In all figures, the data is represented as mean201
± standard deviation (SD).202
203
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Results204
Longitudinal assessment of fungal load and lung anatomy changes by205
combining MRI and BLI206
In this study, mice were rendered leucopenic by two injections of cyclophosphamide.207
All circulating white blood cells were depleted at the time of infection, meaning there208
were 37.0 ± 6.4 neutrophils, 96.3 ± 33.9 lymphocytes, 0 ± 0 monocytes, 3.7 ± 6.4209
eosinophils and 0 ± 0 basophils / µl present in the blood. In leucopenic mice, pulmonary210
infection is characterized by excessive hyphal growth (32). In order to mimic clinic211
management where reversal of immunosuppression is needed for clearance of the212
fungal infection, no additional boosters of cyclophosphamide post infection were213
administered. Consequently, the immune system recovered by day 4, which was214
reflected by a mean neutrophil count of 162.9 ± 23.12 cells / µl blood.215
Visual assessment of the MR images revealed the presence of hyper intense lesions216
within the infected lungs on day 3 and 4 post infection (figure 1A). Both the lung tissue217
volume and cumulative image score quantified from these MR images increased over218
time, reaching significance on day 3 and 4 compared to baseline (figures 1B-C). Upon219
visual inspection of the corresponding bioluminescence images, high signal intensities220
emerged from the lung area on day 3 and 4 after instillation (figure 1D). Furthermore,221
a bioluminescent signal appeared in the nose region starting from day 2. The total222
photon flux quantified from the lung region increased over time, becoming significant223
from day 2 onwards (figure 1E). After comparing BLI and MRI derived parameters, a224
strong positive correlation was identified between the total photon flux and the lung225
tissue volume (R² = 0.65) and between the total photon flux and cumulative image226
score (R² = 0.76) (figure 2A-B). By performing in vivo BLI, longitudinal information was227
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obtained on the amount of viable fungal cells present in the lesions detected on the228
anatomical MR images of infected mouse lungs.229
Non-invasive detection of changes in lesion composition resulting from230
antifungal treatment231
The combination of both imaging modalities could also be used to obtain a better232
understanding of the effect of antifungal treatment on the development and233
composition of lung lesions. To assess differences in therapy response, voriconazole234
treatment was initiated on the day of infection (day 0) or on day 1, 2, 3 after infection235
with a high inoculum. The general condition of the animals was monitored daily and236
anatomical lung MR images were acquired on day 1-5 and 14. None of the animals237
receiving treatment starting at day 3 survived longer than 4 days post infection (figure238
3A). The MR lung images of these animals showed detectable lesions starting from239
day 3 (figure 3C-D, light grey bars). Initiating treatment earlier after infection strongly240
improved the survival rates, as 60% of animals treated from day 2 survived until day241
14 (figure 3A). However, the MRI scans revealed a gradual increase of lung lesions242
over time in all animals, proving that treatment did not prevent disease progression in243
this group (figure 3B-D; second row - medium grey bars). Animals receiving treatment244
from day 1 post infection also displayed an improved survival rate (figure 3A). Unlike245
the previous groups, most mice did not develop MR-detectable lesions within the lungs246
(figure 3B, third row). Only two animals out of five showed clear lesion development247
and needed to be sacrificed by day 4 or 5. As a result, both quantitative MRI-derived248
biomarkers increased on day 4 and 5, followed by a strong decrease by day 14 (figure249
3C-D, dark grey bars). When voriconazole treatment was started immediately after250
infection, 80% of the animals survived until day 14 (figure 3A). Only a limited amount251
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of small lesions developed within the lungs of these animals (figure 3B-D; fourth row -252
black bars).253
The MRI results of the different treatment groups demonstrated a clear relationship254
between the timing of treatment initiation and lesion development rate. To obtain255
information on potential changes in the fungal load during treatment, in vivo BLI scans256
were acquired on day 3, 5 and 9. Intense BLI signals were observed in the lung area257
of animals receiving treatment starting from day 3 (figure 4A). All animals of this258
treatment group needed to be sacrificed at the latest by day 4, explaining the lack of259
data on later time points (figure 4B). Animals receiving treatment starting from day 2260
also showed clear BLI signal from the lung region on day 3 (figure 4C). This signal261
seemed to decrease by day 5 and returned to background levels by day 9 (figure 4D).262
The quantified values were an order of magnitude lower on day 3 compared to the263
group with treatment starting at day 3. The majority of animals in which treatment was264
initiated on day 1 did not show any bioluminescent signal on day 3, 5 and 9 (figure 4E-265
F). However, the two animals showing lesions on the lung MR images also displayed266
clear BLI signal originating from the lung region on day 3. As these animals had to be267
sacrificed by day 5, no BLI data was available on later time points. None of the animals268
receiving treatment from day 0 showed any detectable BLI signal from the lung area269
(figure 4G-H). Both MRI and BLI results indicate that initiation of treatment during the270
early stages of infection has a beneficial effect on both the survival and disease state271
of the animal.272
Improved treatment success in animals infected with a low inoculum of spores273
Therapy might affect disease progression differently when animals are infected with a274
low number of fungal spores, as this model is associated with a high inter-animal275
variation in infection development (8). To further assess this hypothesis, leucopenic276
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mice were instilled with 2 x 105 spores and voriconazole treatment was initiated on day277
0 or day 2. The animals were followed-up by in vivo MRI (day 1-5 and 14) and in vivo278
BLI scans (day 3, 5, 9). A separate control group did not receive treatment and was279
scanned daily until day 7. Half of the non-treated mice needed to be sacrificed by day280
4, while the remaining animals survived until day 7. Lesions could be visualized within281
the lungs of 80 % of the non-treated mice and quantified as an increase in lung tissue282
volume and cumulative image score over time (figure 5A-C). Furthermore, BLI signal283
was detected from the lung region of the majority of animals by day 4, associated by a284
decrease in BLI signal in the surviving mice (figure 5D-F). Within the lungs of mice285
receiving treatment from day 2, small lesions could be detected on the MR images286
from day 4 onwards (figure 5A-C; second row). However, no BLI signal could be287
detected from the lung region of any animal from this group (figure 5E-F). Animals288
receiving treatment from day 0 did not develop any detectable lesions within the lungs289
(figure 5A-C, F). These results show an improved therapeutic response in animals290
infected with a low inoculum, even if treatment is initiated at later time points post291
infection.292
Ex vivo analysis of the lungs support the in vivo imaging findings293
After the last in vivo imaging time point, animals were euthanized and the lungs were294
isolated to perform ex vivo BLI, CFU counting and histology. The lungs of non-treated295
mice infected with a high inoculum showed a strong BLI signal, which was associated296
with high total photon flux values and a high amount of counted colonies (figure 6A-C,297
light grey). Comparable CFU counting results were obtained for the animals where298
treatment commenced on day 3 (figure 6C). On the contrary, no BLI signal could be299
detected from the lungs of mice receiving treatment from day 0 or 1 and no colonies300
could be grown from their lung tissue (figure 6A-C, black and dark grey). Animals301
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receiving treatment from day 2 displayed modest BLI signals in the lungs and302
significantly lower amounts of colonies could be grown from the tissue compared to303
the non-treated group (figure 6A-C, medium grey). For animals infected with a low304
inoculum, the lack of treatment (control group) resulted in a strong BLI signal,305
originating from the lungs (figure 7A-B, light grey). Furthermore, colonies could be306
grown from the lung tissue of most of the animals (figure 7C). In contrast, no clear BLI307
signal could be detected nor could any colony be grown from the lungs for both308
treatment groups (figure 7A-C, black and medium grey).309
Histological analysis revealed the presence of large amounts of fungal elements within310
the lungs of non-treated animals infected with a high inoculum (figure 8A). Fungal311
hyphae invaded the airways and blood vessels, thereby destroying the bronchial lining312
and normal lung structure. Comparable results were obtained for the animals receiving313
treatment from day 3 onwards (data not shown). In contrast, no fungi were detectable314
within the lungs of animals receiving treatment during early stages of infection (figure315
8B). Massive lung lesions were observed in the lungs of animals treated from day 2,316
which mainly consisted of immune cells and only a limited number of fungal elements317
(figure 8C). Infection with a low inoculum of fungal spores resulted in the development318
of lesions in the majority of non-treated animals, which contained large amounts of319
fungal elements (figure 8D). On the contrary, animals receiving treatment from day 0320
and day 2 did not show clear lesions on histological lung sections (figure 8 E-F). In321
conclusion, the ex vivo analysis of the lungs confirmed the in vivo multimodal imaging322
results.323
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Discussion324
This study revealed the potential of combining multimodal imaging approaches to study325
fungal disease development and treatment success. The acquired MR images326
revealed the development of extensive lesions within the lung, which is in line with our327
previously published results (8). In parallel, a strong increase in bioluminescence328
signal intensity was observed from the lung area during the course of disease. These329
observations indicate that the lung lesions detected by MRI are predominantly330
composed of viable fungal cells. Furthermore, a strong bioluminescence signal331
originating from the nose area likely resulted from fungal colonization or infection of332
the nasopharynx or sinuses (28). Switching from an intranasal to an intratracheal333
model could potentially avoid this secondary infection. Multimodal imaging allowed us334
to non-invasively obtain dynamic information on both fungal load and lesion size in a335
leucopenic IPA mouse model, which is of interest when assessing the effect of336
antifungals.337
We also investigated the feasibility to non-invasively monitor the effects of voriconazole338
treatment, including reductions of the fungal load and potential changes in lesion339
formation. Voriconazole was therefore administered at different time points after fungal340
spore instillation. Starting treatment at the latest stage of infection proved to be341
inefficient in counteracting disease progression. This is conform to the clinical situation,342
in which late start of treatment is associated to a poor survival rate (6). On the contrary,343
initiating treatment during the very first stages of infection successfully prevented IPA344
development. The survival rates improved drastically and no pathological changes345
could be detected within the lungs. These results support the clinical concept that early346
diagnosis and treatment administration are essential to successfully recover from IPA347
and underlines the importance of preemptive antifungal treatment in high-risk patient348
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populations. Furthermore, we showed that the treatment efficacy was higher in animals349
infected with a low inoculum, even when treatment was initiated as late as 48 hours350
after instillation. The fungal burden is generally lower in these mice, which facilitates351
controlling the infection by administration of antifungal compound in combination with352
the restoring immune system.353
Most preclinical studies initiate treatment immediately after inducing infection, because354
it increases the success rate for obtaining a positive response. However, studying the355
delayed therapeutic effect of a compound is much more relevant, as it facilitates the356
translation of preclinical results into a clinical setting. Previous studies showed that357
non-invasive imaging techniques can only detect infection as early as 48 hours post358
instillation in the cyclophosphamide mouse model (8, 28). Based on this information, a359
true therapeutic treatment strategy was assessed in our imaging study by initiating360
voriconazole administration on day 2 post infection. The majority of animals survived361
for the total observation period of two weeks, which is indicative for treatment success.362
However, MR imaging revealed the clear development of lung lesions, which kept on363
increasing in size over time. The associated BL images showed a transient increase364
in lung signal, meaning that the lesions detected by MRI still contained a high amount365
of viable fungal cells up to 24 hours after the first administration of voriconazole. At366
later time points, the number of viable fungi decreased drastically, although lesions did367
not resolve on the MR images. Histopathological analysis of those lesions revealed a368
massive influx of immune cells at the lesion sites. All animals were rendered leucopenic369
at the time of infection, but no additional boosters of cyclophosphamide were370
administered. This resulted in recovery of the immune system by day 4 and enabled371
the development of the observed inflammatory response (33). Altogether, these findings372
demonstrate that the improvements observed in animals treated from day 2 resulted373
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from an interplay between the fungicidal effect of voriconazole and the inflammatory374
processes initiated upon reversal of leucopenia. This slows down lesion growth and375
leads to a change in lesion composition rather than the disappearance of induced376
lesions.377
In clinical practice, decisions concerning discontinuation of antifungal treatment in IPA378
patients are based on several factors, including immune status and evidence of379
resolution of clinical signs and symptoms of disease (6, 7). In general, the improvement380
of lesions detected by CT is considered as strong evidence of treatment success.381
However, multiple clinical studies revealed that a worsening of pulmonary lesions is382
not necessarily associated with progressing IPA (34-36). Antifungal treatment is,383
whenever possible, combined with a reduction of immunosuppressive therapy to384
improve patient outcome, but neutrophil recovery can potentially result in the385
development of a pulmonary immune reconstitution inflammatory syndrome (IRIS).386
This syndrome causes a massive influx of immune cells at the site of infection, leading387
to an increase in lesion size and thus a worsening of radiological findings (34, 35). Both388
IRIS and refractory IPA are associated with an increase in lesion volume on CT389
images, making it difficult to distinguish between these two different conditions390
although both require different treatment approaches. There is a need to gather more391
information on IRIS in the context of IPA management and its impact on disease392
recovery. Preclinical research could play a role in assessing new treatment and393
management options, as it was shown in our study that a potential development of IRIS394
can non-invasively be identified in a leucopenic IPA mouse model by the combined395
use of BLI and MRI. However, further in depth studies are needed to confirm the396
development of IRIS and may require a larger number of animals and the use of397
additional markers. This can then be combined by the proposed multimodal imaging398
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approach to longitudinally assess the impact of adapting the treatment regimen on the399
lesion composition and outcome of the subject.400
In conclusion, we showed that the combination of BLI and MRI is highly suitable to401
evaluate different aspects of progressing IPA in leucopenic mice, as it provides402
complementary information on dynamic changes in fungal load as well as lung lesion403
development. Furthermore, we were able to gain insights in therapy-induced changes404
concerning both the extent and the composition of lesions, which is crucial to fully405
comprehend different aspects of disease recovery or deterioration. We believe that406
multimodal imaging will become increasingly important in future preclinical studies as407
a tool to evaluate the in vivo efficacy of therapeutic compounds in a time-efficient408
manner.409
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Figures & figure legends 
 
Figure 1: Multimodal imaging of non-treated mice infected with a high inoculum 1 
of A. fumigatus spores. (A) Representative 3D-UTE MR images of the lung before 2 
(Baseline) and after infection. (B-C) Graphs representing the lung tissue volume and 3 
cumulative image score quantified from the 3D-UTE MR images. (D) Representative 4 
BL images acquired before (Baseline) and after infection. (E) Graph representing the 5 
total photon flux quantified from the BLI images based on a circular ROI covering the 6 
complete lung region. Error bars represent SD of multiple mice (n = 10). *: p < 0.05; **: 7 
p < 0.01; ***: p < 0.001.   8 
 Figure 2: Agreement between parameters quantified from BLI and MRI. (A) Linear 9 
regression analysis of the BLI-derived total photon flux versus the MRI-derived lung 10 
tissue volume. (B) Linear regression analysis of the BLI-derived total photon flux versus 11 
the MRI-derived cumulative image score, expressed in arbitrary units. Dashed lines 12 
represent the 95% confidence band. 13 
 
 Figure 3: MR imaging of animals infected with a high inoculum of A. fumigatus 14 
spores receiving voriconazole at different time points. (A) Survival curve including 15 
all treatment groups. (B) Representative 3D-UTE MR images of the lung before 16 
(Baseline) and after infection of all treatment groups. (C-D) Graphs representing the 17 
lung tissue volume and cumulative image score quantified from the 3D-UTE MR 18 
images for all treatment groups. Error bars represent SD of multiple mice (n = 5 per 19 
treatment group). *: p < 0.05; **: p < 0.01; ***: p < 0.001. 20 
 
 
 
 
 
 Figure 4: Bioluminescence imaging of animals infected with a high inoculum of 21 
A. fumigatus spores receiving voriconazole from different time points. 22 
Representative BLI images and associated graphs showing the total photon flux of 23 
infected mice receiving treatment from day 3 (A-B), day 2 (C-D), day 1 (E-F) or 24 
immediately after infection (G-H). Error bars represent SD of multiple mice (n = 5 per 25 
treatment group).  26 
 
 Figure 5: Multimodal imaging of mice infected with a low inoculum of A. 27 
fumigatus spores. (A) Representative 3D-UTE lung MR images of non-treated 28 
animals and animals receiving voriconazole from day 2 or immediately after infection. 29 
(B-C) Graphs representing the lung tissue volume and cumulative image score 30 
quantified from the 3D-UTE MR images for all animal groups. (D) Representative BLI 31 
images of non-treated animals on day 3 and 4 after infection. (E) Representative BLI 32 
images of animals receiving treatment from day 2 on day 3, 5 and 9 after infection. (F) 33 
Graphs representing the total photon flux quantified from the BLI images for all animal 34 
groups. Error bars represent SD of multiple mice (n = 5 per animal group). 35 
 
 
 
 
 Figure 6: Ex vivo quantification of the fungal load for treated and non-treated 36 
animals infected with a high inoculum. (A) Representative ex vivo BLI images of 37 
lungs isolated after the last imaging time point. (B) Graph representing the total photon 38 
flux quantified from the ex vivo BLI images using a circular ROI covering the lungs. (C) 39 
Graph representing the amount of counted colonies per gram of lung tissue. Error bars 40 
represent SD. *: p < 0.05; **: p < 0.01; ***: p < 0.001. 41 
 
 
 
 
 
 
 Figure 7: Ex vivo quantification of the fungal load for treated and non-treated 42 
animals infected with a low inoculum. (A) Representative ex vivo BLI images of 43 
lungs isolated after the last imaging time point. B) Graph representing the total photon 44 
flux quantified from the ex vivo BL images using a circular ROI covering the lungs. (C) 45 
Graph representing the amount of counted colonies per gram of lung tissue. Error bars 46 
represent SD. 47 
 
 
 
 
 
 
 Figure 8: Light microscopy images of PAS-stained lung sections. Representative 48 
images of mice infected with a high inoculum of fungal spores without treatment (A) or 49 
after receiving treatment from day 0 (B) or day 2 (C). Representative images of mice 50 
infected with a low inoculum of fungal spores without treatment (D) or after receiving 51 
treatment from day 0 (E) or day 2 (F). The scale bars (upper left corner) measure 100 52 
µm. For both high and low inoculum groups, the lungs of non-treated animals were 53 
isolated on day 4 and the lungs of treated animals on day 14 post infection. 54 
